Weekly Recap: DoD funding for NexoBrid and VALUE Phase III reassessment

MediWound Ltd. (NASDAQ:MDWD) secured $3.3M in non-dilutive DoD funding to bring a room-temperature NexoBrid formulation toward IND readiness while advancing a global Phase III VALUE trial of EscharEx for venous leg ulcers, with an interim reassessment and enrollment due by end—Q1 2027.Previous Week…